SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Sotac Pharmaceuticals Ltd (SOTAC)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: SOTAC Pharmaceuticals & Drugs | Small Cap | Sotac Pharmaceutical Share Price

BSE Share Price
Not Listed

Sotac Pharmaceuticals Ltd (SOTAC)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: SOTAC Pharmaceuticals & Drugs | Small Cap | Sotac Pharmaceutical Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹123 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹4.5
TTM Sales
₹71.9 Cr.
Book Value per Share
₹52.3
P/E Ratio
24.94
Lower than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
2.12
Lower than its 5-year historical median
Price to Sales (P/S)
1.71
Lower than its 5-year historical median
EV/EBITDA
12.68
Lower than its 5-year historical median
Dividend Yield
0.08%
Profitability Efficiency
Return on Equity (ROE)
9.42%
In line with industry median
Return on Capital Employed (ROCE)
11.44%
In line with industry median
Return on Assets (ROA)
5.93%
Operating Profit Margin
12.3%
Net Profit Margin
7.65%
Gross Profit Margin
14.3%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-7.05%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-22.87%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-17.04%
Asset Quality
Promoter Holding
72.85%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹47 Cr.
Equity
₹11.1 Cr.
Face Value
₹10
All Time Low / High
- / -

Sotac Pharmaceuticals stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Locked
Login to view analysis.

Valuation

Locked
Login to view analysis.

Price Trend

Locked
Login to view analysis.
Q.1 Is Sotac Pharmaceuticals Ltd a good quality company?
Sotac Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Sotac Pharmaceuticals Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Sotac Pharmaceuticals Ltd vs industry peers?
Sotac Pharmaceuticals Ltd revenue CAGR is 16.88%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Sotac Pharmaceuticals Ltd?
Promoters hold 72.85% of the Sotac Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Sotac Pharmaceuticals Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of -5.21% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sotac Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ11%16.4%41.6%29.8%19.3%11.4%-
Value Creation
Index ⓘ		-0.20.22.01.10.4-0.2-

Growth Parameters ⓘ
Sales ⓘ28.643.473.25867.162.472
Sales YoY Gr.-51.9%68.4%-20.7%15.8%-7.1%-
Adj EPS ⓘ0.91.15.75.65.14.14.5
YoY Gr.-21.6%431.8%-1.8%-8.9%-20.2%-
BVPS (₹) ⓘ4.25.28.814.343.74852.3
Adj Net
Profit ⓘ		0.70.94.64.55.64.55
Cash Flow from Ops. ⓘ-0.32.43.68.5-19.8-6.1-
Debt/CF from Ops. ⓘ-28.62.82.11.3-0.6-3.3-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNA16.9%-5.2%-7.1%
Adj EPS ⓘNA35.8%-10.6%-20.2%
BVPSⓘNA62.9%75.9%9.8%
Share Price - - -5% -7.5%

Key Financial Parameters ⓘ

Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		20.922.780.932.116.38.98.9
Op. Profit
Mgn % ⓘ		7.26.51114.214.912.313.2
Net Profit
Mgn % ⓘ		2.526.37.88.47.26.8
Debt to
Equity ⓘ		2.11.610.90.20.4-
Working Cap
Days ⓘ		01081011711992940
Cash Conv.
Cycle ⓘ		0-5-15-8441150

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales294373586762
Operating Expenses ⓘ + 274167505755
Manufacturing Costs225576
Material Costs213456404544
Employee Cost 122211
Other Costs ⓘ 224334
Operating Profit ⓘ 2368108
Operating Profit Margin (%) 7.2%6.5%8.5%14.2%14.9%12.3%
Other Income ⓘ + 000012
Exceptional Items ⓘ 000000
Interest ⓘ 011111
Depreciation ⓘ 111232
Profit Before Tax ⓘ 115686
Tax ⓘ 001122
Profit After Tax 113465
PAT Margin (%) 2.5%2.0%4.5%7.8%8.6%7.7%
Adjusted EPS (₹)0.91.14.15.65.24.3
Dividend Payout Ratio (%)0%0%14%0%0%2.30%

Valuation of Sotac Pharmaceutical - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 347124853
Share Capital ⓘ 22281111
Reserves ⓘ 12533742
Debt +7669912
Long Term Debt331746
Short Term Debt445256
Minority Interest000000
Trade Payables10102018159
Others Liabilities ⓘ 11316411
Total Liabilities ⓘ 212236557685

Fixed Assets

Net Fixed Assets ⓘ +669141817
Gross Block91011182425
Accumulated Depreciation342469
CWIP ⓘ 000000
Investments ⓘ 22041113
Inventories245101110
Trade Receivables8613112225
Cash Equivalents 0001010
Others Assets ⓘ 231061320
Total Assets ⓘ 212236557685

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + -0249-20-6
PBT ⓘ 115686
Adjustment ⓘ 223202
Changes in Working Capital ⓘ -2-0-32-26-14
Tax Paid ⓘ -0-0-1-2-2-1
Cash Flow From Investing Activity ⓘ + -2-1-3-11-13-2
Capex 0-1-4-7-6-1
Net Investments -2-00-4-7-2
Others ⓘ 000011
Cash Flow From Financing Activity ⓘ + 2-1-012238
Net Proceeds from Shares ⓘ 1009330
Net Proceeds from Borrowing ⓘ -4-0-66-21
Interest Paid ⓘ -0-1-1-1-1-1
Dividend Paid ⓘ 00-0000
Others ⓘ 5-06-2-78
Net Cash Flow ⓘ -0-0010-9-0

Financial Ratio

PARTICULARSMar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)20.9322.7158.2348.2919.239.42
ROCE (%)10.9816.4341.5629.7619.2811.44
Asset Turnover Ratio1.352.022.511.271.030.77
PAT to CFO Conversion(x)-021.332.25-3.33-1.2
Working Capital Days
Receivable Days104.2059.4046.2075.7091.10136.60
Inventory Days29.7025.7022.9047.105662
Payable Days169.60108.5098.10173133100.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sotac Pharmaceuticals Ltd FAQs

The current trading price of Sotac Pharmaceutical on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Sotac Pharmaceutical stood at ₹122.7 Cr

The latest P/E ratio of Sotac Pharmaceutical as of 31-Dec-1969 is 24.94.

The latest P/B ratio of Sotac Pharmaceutical as of 31-Dec-1969 is 2.12.

The 52-week high of Sotac Pharmaceutical is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sotac Pharmaceutical is ₹71.88 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sotac Pharmaceuticals Ltd is a average quality company.

The key valuation ratios of Sotac Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Sotac Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Sotac Pharmaceuticals Ltd

The company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 (Partnership Act) in the name and style of Sotac Pharmaceuticals, pursuant to a deed of partnership dated December 10, 2014. Thereafter Sotac Pharmaceuticals was converted from Partnership Firm to a Private Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of Sotac Pharmaceuticals Private Limited and received a certificate of incorporation dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat. Later on the company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the Company held on November 12, 2022 and the name of the Company was changed to Sotac Pharmaceuticals Limited. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated November 22, 2022 was issued by the Registrar of Companies, Ahmedabad.

Sotac Pharmaceuticals is in business of manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis. Its business is majorly on principle to principle basis with different marketers. The company caters to corporate clients on loan licence and/or contract manufacturing basis. The company has commenced manufacturing facility in year 2017, hence, the company has experience of more than 5 years in the current line of business of the company. In year 2017, the company’s manufacturing facility was installed with capacity to manufacture 90 crore tables / year, 14 crore Capsules / year.

Business area of the company

The company specializes in the production of high-quality pharmaceutical products on a loan license or contract manufacturing basis. It has a diverse product portfolio that includes a wide range of pharmaceuticals, nutraceuticals, and food products.

Key Events/Milestone/ Achievement

  • 2015: The company was incorporated as a private limited company under the name Sotac Pharmaceuticals Private Limited.
  • 2019: Recognised as ‘Fastest Growing Indian Company’ with and Excellence Award by International Achievers Conference.
  • 2021: Received ‘Indo Global award for Business Excellence’ 2022.
  • 2022: The Company has acquired 53,25,000 Equity Shares in SOTAC Healthcare Private Limited making it subsidiary of the Company.
  • 2022: The Company has acquired 99,995 Equity Shares in SOTAC Research Private Limited making it wholly owned subsidiary of the Company.
  • 2022: The Company was converted into Public Limited Company under the name of ‘Sotac Pharmaceuticals Limited’.
  • 2022: Received recognition as for ‘Fastest Expansion of Project’ by Sanand Industries Association (SIA).
  • 2022: Recognized as one of the ‘Top 10 Pharma Contract Manufacturers in India’ by India Pharma Outlook.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×